Compare
Ligand Pharmaceuticals Inc vs Arvinas, Inc. vs Keros Therapeutics, Inc. vs Anaptysbio, Inc
| Latest fiscal year | Ligand Pharmaceuticals Inc LGND | Arvinas, Inc. ARVN | Keros Therapeutics, Inc. KROS | Anaptysbio, Inc ANAB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $268.09M | $262.60M | $244.06M | $234.60M |
| Revenue growth (YoY) | +60.4% | -0.3% | n/m | +157.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | 15.3% | -45.1% | 27.7% | 20.4% |
| Net margin | 46.4% | -30.8% | 35.7% | -5.6% |
| Net income | $124.45M | -$80.80M | $87.01M | -$13.23M |
| EPS (Diluted) | $6.13 | -$1.14 | $2.30 | -$0.46 |
| Operating cash flow | $49.36M | -$273.80M | $107.50M | $19.70M |
| Free cash flow | $48.91M | -$275.70M | $105.95M | $19.61M |
| Cash & equivalents | $174.93M | $142.90M | $287.42M | $238.20M |
| Total assets | $1.56B | $717.90M | $338.02M | $364.39M |
| Total liabilities | $543.42M | $284.00M | $34.89M | n/a |
| Shareholders' equity | $1.02B | $433.90M | $303.13M | $37.21M |
| Return on year-end equity | 12.2% | -18.6% | 28.7% | -35.6% |
| Shares outstanding | 19.77M | 63.50M | 19.54M | 28.02M |
Revenue, most recent five fiscal years
| Fiscal year | Ligand Pharmaceuticals Inc | Arvinas, Inc. | Keros Therapeutics, Inc. | Anaptysbio, Inc |
|---|---|---|---|---|
| Latest | $268.09M Ended 2025-12-31 | $262.60M Ended 2025-12-31 | $244.06M Ended 2025-12-31 | $234.60M Ended 2025-12-31 |
| 1 year earlier | $167.13M Ended 2024-12-31 | $263.40M Ended 2024-12-31 | $3.55M Ended 2024-12-31 | $91.28M Ended 2024-12-31 |
| 2 years earlier | $131.31M Ended 2023-12-31 | $78.50M Ended 2023-12-31 | $151.0K Ended 2023-12-31 | $17.16M Ended 2023-12-31 |
| 3 years earlier | $196.25M Ended 2022-12-31 | $131.40M Ended 2022-12-31 | $0 Ended 2022-12-31 | $10.29M Ended 2022-12-31 |
| 4 years earlier | $241.54M Ended 2021-12-31 | $53.60M Ended 2021-12-31 | $20.10M Ended 2021-12-31 | $63.17M Ended 2021-12-31 |